Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Subscribe To Our Newsletter & Stay Updated
